The neurofibromatoses are genetic disorders that cause tumors to grow in the nervous system. The tumors begin in the supporting cells that make up the nerves and the myelin sheath--the thin membrane that envelops and protects the nerves. These disorders cause tumors to grow on nerves and produce other abnormalities such as skin changes and bone deformities. Although many affected persons inherit the disorder, between 30 and 50 percent of new cases arise spontaneously through mutation (change) in an individual's genes. Once this change has taken place, the mutant gene can be passed on to succeeding generations. Scientists have classified the disorders as neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), and schwannomatosis, a type that was once considered to be a variation of NF2. NF1 is the more common type of the neurofibromatoses. In diagnosing NF1, a physician looks for changes in skin appearance, tumors, or bone abnormalities, and/or a parent, sibling, or child with NF1. Symptoms of NF1, which may be evident at birth and nearly always by the time the child is 10 years old, may include light brown spots on the skin ("cafe-au-lait" spots), two or more growths on the iris of the eye, a tumor on the optic nerve, a larger than normal head circumference, and abnormal development of the spine, a skull bone, or the tibia. NF2 is less common and is characterized by slow-growing tumors on the eighth cranial nerves. The tumors cause pressure damage to neighboring nerves. To determine whether an individual has NF2, a physician looks for eighth nerve tumors, cataracts at an early age or changes in the retina that may affect vision, other nervous system tumors and similar signs and symptoms in a parent, sibling, or child. The distinctive feature of schwannomatosis is the development of multiple schwannomas (tumors made up of certain cells) everywhere in the body except on the vestibular branch of the 8th cranial nerve. The dominant symptom is pain, which develops as a schwannoma enlarges or compresses nerves or adjacent tissue. Some people may develop numbness, tingling, or weakness in the fingers and toes.
Surgery is often recommended to remove the tumors. Some NF1 tumors may become cancerous, and treatment may include surgery,
radiation, or chemotherapy. Surgery, radiation, and chemotherapy also may be used to control or reduce the size of optic nerve
tumors when vision is threatened. Some bone malformations can be corrected surgically
For NF2, improved diagnostic technologies, such as MRI, can reveal tumors as small as a few millimeters in diameter, thus
allowing early treatment. Surgery to remove tumors completely is one option but may result in hearing loss. Surgery also can
correct cataracts and retinal abnormalities.
There is no currently accepted medical treatment or drug for schwanomatosis, but surgical management is often effective. Pain
usually subsides when tumors are removed completely. Genetic testing is available for families with documented cases of NF1
and NF2 but such testing for schwannomatosis currently does not exist.
Neurofibromatosis, Inc. Post Office Box 66884 Chicago, IL 60666 admin@nfnetwork.org http://www.nfnetwork.org/ Tel: 630-627-1115 800-942-6825 |
Acoustic Neuroma Association 600 Peachtree Parkway Suite 108 Cumming, GA 30041 info@anausa.org http://www.anausa.org Tel: 770-205-8211 877-200-8211 Fax: 770-205-0239/877-202-0239 |
Children's Tumor Foundation 95 Pine Street 16th Floor New York, NY 10005 info@ctf.org http://www.ctf.org Tel: 800-323-7938 212-344-6633 Fax: 212-747-0004 |
March of Dimes 1275 Mamaroneck Avenue White Plains, NY 10605 askus@marchofdimes.com http://www.marchofdimes.com Tel: 914-997-4488 888-MODIMES (663-4637) Fax: 914-428-8203 |
National Cancer Institute (NCI) National Institutes of Health, DHHS 6116 Executive Boulevard, Ste. 3036A, MSC 8322 Bethesda, MD 20892-8322 cancergovstaff@mail.nih.gov http://cancer.gov Tel: 800-4-CANCER (422-6237) 800-332-8615 (TTY) |
Prepared by:
Office of Communications and Public Liaison
National Institute of Neurological Disorders and Stroke
National Institutes of Health
Bethesda, MD 20892
NINDS health-related material is provided for information purposes only and does not necessarily represent endorsement by or an official position of the National Institute of Neurological Disorders and Stroke or any other Federal agency. Advice on the treatment or care of an individual patient should be obtained through consultation with a physician who has examined that patient or is familiar with that patient's medical history.
All NINDS-prepared information is in the public domain and may be freely copied. Credit to the NINDS or the NIH is appreciated.
Last updated January 13, 2012